Mr. Bernard is currently the Chief Executive Officer (CEO) and Managing Director of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies. His extensive experience in the life sciences sector includes significant roles at bioMérieux SA, where he served as Corporate Vice President for Global Commercial Operations and Investor Relations. His appointment is seen as a strategic move to enhance Bruker's leadership in life-science research and diagnostics.
Frank H. Laukien, Chairman, President, and CEO of Bruker Corporation, expressed enthusiasm about Mr. Bernard joining the Board, highlighting his successful track record and strategic insights. Laukien stated, "Bruker is delighted that Thierry is joining our Board. I have admired his successful track record, astute strategic initiatives, and outstanding execution for many years. I am convinced that Thierry will be an excellent addition to our Board of Directors as we further develop our leadership position in life-science research, biopharma, and diagnostic solutions in the post-genomic era."
Mr. Bernard's compensation as a director will align with that of other non-employee directors at Bruker, as detailed in the company's definitive proxy statement for the 2025 Annual Meeting of Stockholders. There are no other arrangements or understandings between Mr. Bernard and any other person regarding his election as a director, and he is not involved in any transactions with the company that would require disclosure under Item 404(a) of Regulation S-K.
The company plans to file an amended Form 8-K to disclose Mr. Bernard's committee assignments once they are determined. This leadership change is expected to positively impact Bruker's strategic direction and operational execution, enhancing its competitive position in the market.
